文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

盆腔功能性骨髓剂量体积参数与宫颈/子宫内膜癌调强放疗伴或不伴同步化疗期间急性血液学毒性关系的前瞻性单臂研究

A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
PubMed 文献 · Radiat Oncol · 2023-11-27

这项前瞻性单臂II期试验自2016年12月至2021年9月纳入97例接受调强放疗的宫颈/子宫内膜癌患者,用FLT-PET/CT将盆腔功能性骨髓分为FBM1和FBM2两级,分析其剂量体积参数与≥2级血液学毒性的关系。多因素回归显示FBM1的Dmax与≥2级白细胞减少、FBM1的V10与≥2级贫血、FBM2的Dmean与≥2级血小板减少显著相关,作者推荐FBM1 Dmax<53 Gy、V10<95%、FBM2 Dmean<33 Gy。

要点

  • 放疗期间≥2级白细胞减少、中性粒细胞减少、血小板减少和贫血发生率分别为63.9%、45.4%、19.6%和38.8%。
  • FBM1 Dmax与≥2级白细胞减少相关(OR=1.277,95%CI 1.067-1.528,P=0.008)。
  • 作者推荐的最佳剂量约束为FBM1 Dmax<53 Gy、V10<95%、FBM2 Dmean<33 Gy。

核心结论

  • 宫颈/子宫内膜癌患者≥2级血液学毒性通常发生在放疗第4周。
  • FBM1的Dmax和V10、FBM2的Dmean与≥2级血液学毒性发生显著相关。
  • 作者推荐的最佳剂量约束为FBM1 Dmax<53 Gy、V10<95%、FBM2 Dmean<33 Gy。

研究设计与样本

  • 本研究为前瞻性单臂II期试验,自2016年12月至2021年9月纳入97例接受调强放疗的宫颈/子宫内膜癌患者。
  • 放疗期间每周复查血常规。
  • 采用单因素和多因素回归方法分析FBM1/2剂量体积参数与≥2级血液学毒性的关系。
  • 采用ROC曲线确定FBM1/2剂量体积参数的截断值。

主要发现

  • 放疗期间≥2级白细胞减少、中性粒细胞减少、血小板减少和贫血的发生率分别为63.9%、45.4%、19.6%和38.8%,中位发生时间分别为第29天、第42天、第35天和第31天。
  • 多因素回归分析显示FBM1的Dmax与≥2级白细胞减少显著相关(OR=1.277,95%CI 1.067-1.528,P=0.008)。
  • FBM2的Dmean与≥2级血小板减少显著相关(OR=1.262,95%CI 1.066-1.494,P=0.007)。
  • FBM1的V10与≥2级贫血显著相关(OR=1.198,95%CI 1.003-1.431,P=0.046)。
  • FBM1 Dmax<53 Gy患者的≥2级白细胞减少发生率低于FBM1 Dmax≥53 Gy患者(53.4% vs. 95.8%,P<0.001);FBM2 Dmean<33 Gy患者的≥2级血小板减少发生率低于FBM2 Dmean≥33 Gy患者(0 vs. 28.4%,P<0.001);FBM1 V10<95%患者的≥2级贫血发生率低于FBM1 V10≥95%患者(24.4% vs. 57.1%,P=0.003)。

关键数值与推荐

  • 作者推荐的最佳剂量约束为FBM1 Dmax<53 Gy、V10<95%,以及FBM2 Dmean<33 Gy。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: FLT-PET/CT can accurately identify and locate functional bone marrow (FBM) with hematopoietic capability, the FBM were divided into two levels as FBM1 (strongest hemopoietic ability region)and FBM2 (moderate hemopoietic ability region) via FLT-PET/CT. The purpose of this study was to explore the relationship between dose-volume parameters of pelvic FBM and hematologic toxicity (HT) during radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer. METHODS: From December 2016 to September 2021, ninety-seven uterine cervical/endometrial cancer patients received intensity-modulated radiation therapy were prospectively recruited in this single-arm, prospective, phase II trial. Blood counts were reviewed weekly during radiotherapy. Single- and multifactor regression methods were used to analyze the relationships between dose-volume parameters of FBM1/2 and grade ≥ 2 HT. ROC curves were used to determine the cutoff values for the dose-volume parameters of FBM1/2. RESULTS: The incidence of grade ≥ 2 leukopenia, neutropenia, thrombocytopenia and anemia in patients during radiotherapy was 63.9%, 45.4%, 19.6% and 38.8% respectively, and the median occurrence time was the 29th, 42th, 35th and 31th day, respectively. Multivariate regression analysis showed that the Dmax of FBM1 was significantly related to grade ≥ 2 leukopenia (OR = 1.277 95% CI 1.067-1.528, P = 0.008), Dmean of FBM2 was significantly related to grade ≥ 2 thrombocytopenia (OR = 1.262 95% CI 1.066-1.494, P = 0.007), and V10 of FBM1 was significantly related to grade ≥ 2 anemia (OR = 1.198 95% CI 1.003-1.431, P = 0.046). The incidence of grade ≥ 2 leukopenia for patients with FBM1 Dmax < 53 Gy was lower than that for patients with FBM1 Dmax ≥ 53 Gy (53.4% vs. 95.8%, P < 0.001). The incidence of grade ≥ 2 thrombocytopenia in patients with FBM2 Dmean < 33 Gy was lower than that in patients with FBM2 Dmean ≥ 33 Gy (0 vs. 28.4%, P < 0.001). The incidence of grade ≥ 2 anemia for patients with FBM1 V10 < 95% was lower than that in patients with FBM1 V10 ≥ 95% (24.4% vs. 57.1%, P = 0.003). CONCLUSIONS: Grade ≥ 2 HT usually occurs in the 4th week of radiotherapy for patients with uterine cervical/endometrial cancer. The Dmax and V10 of FBM1 and the Dmean of FBM2 were significantly associated with the occurrence of grade ≥ 2 HT. The recommended optimal dose constraints were FBM1 Dmax < 53 Gy, V10 < 95%, and FBM2 Dmean <33 Gy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen H, Zhong Q, Liu Y, et al. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer. Radiat Oncol. 2023. PMID: 38012675. doi:10.1186/s13014-023-02380-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。